ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

1:00PM-2:30PM: Abstract Number: 1681

Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study

Abstracts: RA – Treatments: New Approaches

1:00PM-2:30PM: Abstract Number: 1677

Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial

Abstracts: RA – Treatments: New Approaches

1:00PM-2:30PM: Abstract Number: 1659

Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking

Abstracts: RA – Etiology and Pathogenesis I

1:00PM-2:30PM: Abstract Number: 1692

Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

1:00PM-2:30PM: Abstract Number: 1660

Systemic Inflammation and Transcriptional Reprogramming Contribute to Progression to Active Rheumatoid Arthritis in ACPA+ Individuals

Abstracts: RA – Etiology and Pathogenesis I

1:00PM-2:30PM: Abstract Number: 1672

The Evaluation of SLE Outcome Measures in Telemedicine

Abstracts: Patient Outcomes, Preferences, & Attitudes I

1:00PM-2:30PM: Abstract Number: 1685

The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers

1:00PM-2:30PM: Abstract Number: 1691

Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

1:00PM-2:30PM: Abstract Number: 1651

Unlocking the Secrets of Breg Dysfunction in Lupus: Glycosylation Patterns as Therapeutic Targets

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

1:00PM-2:30PM: Abstract Number: 1686

Urine Proteomics in Class II Lupus Nephritis Reveals Immune Activation and Pro-Fibrotic Signatures

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers

1:00PM-2:30PM: Abstract Number: 1662

Using Circulating Soluble Serum Mediator Profiles to Understand the Mechanisms Driving Disease Flare and Drug-free Remission in Rheumatoid Arthritis

Abstracts: RA – Etiology and Pathogenesis I

1:00PM-2:30PM: Abstract Number: 1674

Variability in Pain and Depression Measures Between Adolescent Patients with Rheumatic Disease and Caregivers

Abstracts: Patient Outcomes, Preferences, & Attitudes I

1:00PM-2:30PM: Abstract Number: 1669

Will Investigators Enroll? A Vignette Study to Gauge Investigator Equipoise in a Trial of Surgery vs. Nonoperative Therapy in Subjects with Meniscal Tear and Persistent Pain Following Physical Therapy

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

3:00PM-4:30PM: Abstract Number: 1753

A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases

Abstracts: SLE – Treatment I: Cellular Therapy

3:00PM-4:30PM: Abstract Number: 1760

A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis

Abstracts: SpA Including PsA – Treatment I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].